China woman suffers brain haemorrhage, in coma after sunbathing to improve health
The incident recently unfolded in Zhejiang province, southeastern China, when the woman, surnamed Wang, tried a traditional Chinese medicine (TCM) remedy she had heard about.
The remedy apparently said that 'sunbathing your back can warm the yang energy, dispel dampness and cure illnesses'.
Around noon, Wang lay face-down in an open area outside her home for two hours.
Experts say that when it comes to sunbathing, keeping strict control over the amount of exposure to the sun is vital. Photo: Shutterstock
However, shortly after returning indoors, she collapsed and lost consciousness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
12 minutes ago
- South China Morning Post
China approving innovative drugs at record pace as discovery momentum shifts from West
China is making inroads in the race for innovative pharmaceuticals, with a record number of drug approvals this year amid growing appeals for multinational giants to run onshore research entities. Authorities approved 43 innovative drugs in the first half of 2025, marking a 59 per cent year-on-year increase and nearly matching the total of 48 approvals for all of last year, state broadcaster CCTV reported on Wednesday, citing data from the National Medical Products Administration (NMPA). Many of the 43 innovative drugs approved for market launch are for serious conditions such as cancer, metabolic disorders and immune diseases, the report said. 'China's reform of drug review and approval processes has enabled pharmaceutical companies to better forecast their returns on R&D investments … making them more willing to pursue long-term, high-risk innovative drug development,' said Yang Ting, director of the NMPA's drug registration department, in an interview with CCTV. China is the world's second-largest biomedicine market, and global players have been increasingly expanding their presence there. Also in the year's first half, China set a record for licensing out innovative drugs – referring to rights granted to overseas markets – with a total value of US$48.4 billion, according to figures from mainland pharmaceutical consultancy DrugTimes. To further refine manufacturing processes and improve drug quality, additional approval procedures are often required after a drug's market launch.
South China Morning Post
5 hours ago
- South China Morning Post
Stay alert to chikungunya fever threat, leading expert tells Hongkongers
Hongkongers should stay vigilant against chikungunya fever, leading expert Yuen Kwok-yung has said, stressing that the mosquito-borne disease could cause prolonged and severe joint pain amid weak population immunity. Yuen, chair of infectious diseases at the University of Hong Kong's Department of Microbiology, made the warning on Thursday, following recent outbreaks in mainland China, including 3,000 cases reported in Foshan city in Guangdong province. While no chikungunya fever cases have been registered in Hong Kong since 2020, Yuen has said that any potential outbreak in the city could be on a large scale. 'Any outbreak could be major because we have no immunity, so we should not take it lightly,' he said during a radio show. 'Normally, you might only experience a fever, rash and swollen joints. Most people will be fine, but you must not forget that if you have a chronic illness, it can be very serious to those who are very old or very young. 'It can affect your brain and cause inflammation of the retina or even retinal detachment. It can also impact the heart.'
South China Morning Post
a day ago
- South China Morning Post
China GLP-1 drug study suggests slim chance weight stays off after treatment
A Chinese analysis of prescription anti-obesity medications has added to evidence that people who use popular GLP-1 drugs such as Ozempic to shed pounds face the prospect of 'significant' weight rebound once they stop using them – challenges similar to those presented by more traditional slimming strategies. Patients saw 'significant weight' return eight weeks after anti-obesity medications (AOMs) were stopped, which continued after 20 weeks, the team from Peking University People's Hospital wrote in an article published in the peer-reviewed journal BMC Medicine on Tuesday. 'Weight regain is common in various weight-loss strategies and it is necessary to establish long-term anti-obesity treatment in clinical practice,' the researchers said. Worldwide, 2½ billion adults were overweight in 2022 and 890 million of them were obese, according to the World Health Organization 01:20 China approves popular weight-loss drug Wegovy produced by Danish firm Novo Nordisk China approves popular weight-loss drug Wegovy produced by Danish firm Novo Nordisk
